Omar Rashdan

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Health Insurance

Chronic Lymphocytic Leukemia

Top Venues

Journal of medical economics

The Annals of pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Nimer S Alkhatib, Eman Massad, Omar Rashdan, Wendy Max, Shiraz Halloush, Hamza Abumansour, Ala'a Alkhatib, Reema A Karasneh, Samah Al-Shatnawi, Tariq Qirim, Feras Hawari, Said Alkhatib
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs. Journal of medical economics (2024)
Omar Rashdan
Estimating the indirect economic burden of cancer in Jordan: a retrospective observational study. BMJ open 14 (6) (2024)
Omar Rashdan
Estimating the indirect economic burden of cancer in Jordan: a retrospective observational study. BMJ open 14 (6) (2024)
Omar Rashdan
Estimating the indirect economic burden of cancer in Jordan: a retrospective observational study. BMJ open 14 (6) (2024)
Omar Rashdan
Estimating the indirect economic burden of cancer in Jordan: a retrospective observational study. BMJ open 14 (6) (2024)
Nimer S Alkhatib, Eman Massad, Omar Rashdan, Wendy Max, Shiraz Halloush, Hamza Abumansour, Ala'a Alkhatib, Reema A Karasneh, Samah Al-Shatnawi, Tariq Qirim, Feras Hawari, Said Alkhatib
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs. Journal of medical economics 27 (1) (2024)
Hala H Halawah, Nimer S Alkhatib, Abdulaali R Almutairi, Mohammad Saleh, Shiraz S Halloush, Omar Rashdan, Lama Masadh, Osama H Abusara, Ivo Abraham
Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. Journal of medical economics (2023)
Shiraz Halloush, Nimer S Alkhatib, Abdulaali R Almutairi, Mathias Calamia, Hala Halawah, Mavis Obeng-Kusi, Martin Hoyle, Omar Rashdan, Jim Koeller, Ivo Abraham
Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective. The Annals of pharmacotherapy (2023)